StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc.

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$945.53−12.23 (-1.28%)

Close on Nov 18, 2026Market cap $97.81BP/E 20.9Yield –

Regeneron Pharmaceuticals CEO Pay Ratio (X:1) [annual] by Year

Regeneron Pharmaceuticals CEO Pay Ratio (X:1) [annual]: 42.00 in FY2025, up 2.4% from a year earlier.

Latest, FY2025
42.00
Period ended Dec 31, 2025
Change on a year earlier
+2.4%
41.00 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below

Where the FY2025 figure comes from

“Accordingly, the ratio of the 2025 annual total compensation of Dr. Schleifer to the median of the 2025 annual total compensation of our employees was approximately 42 to 1”

Source: Proxy Statement (DEF 14A) (regn-20260424.htm, filed 2026-04-24) ↗

Reported in DEF 14A Proxy Statements — CEO Pay Ratio Disclosure.

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up CEO Pay Ratio (X:1) [annual]

Cite this data

StockData. (2026). Regeneron Pharmaceuticals CEO Pay Ratio (X:1) [annual], annual FY2019–FY2025 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/proxy-pay-ratio

See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.

See a number that looks wrong?